Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Cory R Theberge

Ian M Bell

C Blair Zartman

Craig A Stump

Steven N Gallicchio

David A Claremon

Harold G Selnick

Nigel J Liverton

Xufang Zhang

Xu-Fang Zhang

Joseph P Vacca

John A McCauley

Michael R Wood

Craig William Lindsley

Theresa M Williams

Christopher D Cox

Christopher F Claiborne

David James Hallett

Izzat Tiedje Raheem

John W Butcher

Scott E Wolkenberg

Zhijian Zhao

William D Shipe

M Brad Nolt

Elizabeth M Naylor

The present invention is directed to 2-alkoxy pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Alkoxy pyrimidine PDE10 inhibitors

The present invention is directed to compounds of Formula I: I (where A, A, B, B, B, B, D, D, J, K, T, U, V, W, X, Y, Z, R, R, R, R, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. 

Tricyclic anilide spirolactam CGRP receptor antagonists

Compounds of formula I: (wherein variables A, A, A, A, A, A, A, B, E, E, E, E, E, G, Gand Rare as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Bicyclic spirohydantoin CGRP receptor antagonists

Spirohydantoin aryl CGRP receptor antagonists

Compounds of formula I: (wherein variables A, A, A, A, A, A, A, B, E, E, E, E, E, G, G, J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Spirolactam bicyclic CGRP receptor antagonists

The present invention is directed to compounds of Formula I: (where variables A, A, B, J, K, m, n, R, R, Rand Rare as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Bicyclic anilide spirolactam CGRP receptor antagonists

The present invention is directed to compounds of Formula (I): where variables A, A, B, J, K, m, n, R, R, R, Rand X are as defined herein useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. 

Aryl spirolactam CGRP receptor antagonists

Compounds of formula I: (wherein variables A, A, A, A, A, A, A, B, B, B, B, D, D, E, E, E, E, E, G, G, R, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Spirohydantoin tricyclic CGRP receptor antagonists

The present invention is directed to piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

Piperidine glycine transporter inhibitors

Compounds of formula I: (wherein variables A, A, A, A, A, A, A, B, B, B, B, D, D, E, E, E, E, E, G, G, J, K, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Spirolactam tricyclic CGRP receptor antagonists

Compounds of formula I: (wherein variables A, A, A, A, A, A, A, E, E, E, E, E, G, G, J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Spirolactam aryl CGRP receptor antagonists

The present invention is directed to compounds of Formula I: I (where A, A, B, B, B, B, D, D, T, U, V, W, X, Y, Z, R, R?, R, R, R, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. 

Tricyclic anilide spirohydantion CGRP receptor antagonists

The present invention is directed to compounds of the formula: that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Bicyclic anilide spirohydantoin CGRP receptor antagonists

The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Growing community of inventors

King of Prussia, PA, United States of America

Cory R Theberge